Zaviralci imunskih kontrolnih točk so razred zdravil, ki se borijo z imunskim sistemom telesa za boj proti rakavim celicam. Vendar se večina bolnikov ne odzove na te terapije. Obstaja novejši razred zdravil, ki cilja na dva proteina, ki sodelujeta pri zatiranju imunskega odziva telesa proti tumorjem.
Phase I of clinical trials has shown some exciting results, which were conducted in 19 patients suffering from rak with the molecule M7824. These researchers are also undertaking trials with those suffering from rak trebušne slinavke in tiste, ki so okuženi s HPV.
There are many other trials and experiments being taken to treat and zdravljenje raka more effectively in different research institutes. This drug with a dual approach will be a boon in the zdravljenje raka, as with a single molecule, multiple therapies are included.
